Actively Recruiting
AN69ST Verse PS in CBP in Septic Children
Led by Children's Hospital of Fudan University · Updated on 2026-02-17
80
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital of Fudan University
Lead Sponsor
W
West China Second University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different membrane on children with sepsis through a perspective cohort study, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.
CONDITIONS
Official Title
AN69ST Verse PS in CBP in Septic Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the 2005 diagnostic criteria for sepsis
- Age between 29 days and 18 years old
- Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock
- Diagnosis of sepsis within 48 hours before enrollment
You will not qualify if you...
- Unable to obtain informed consent from the patient or authorized representative
- End-stage renal disease requiring chronic dialysis
- Clinical support indicates non-septic shock
- Chest compressions during this hospitalization without immediate return to communication
- Uncontrolled bleeding
- Immunodeficiency diseases
- Received chemoradiotherapy or immunosuppressive therapy within 14 days prior to enrollment
- HIV infection with last known or suspected CD4 count below 50/mm3
- Extensive third-degree burns within the past 7 days
- Known allergy or sensitivity to heparin or history of heparin-induced thrombocytopenia
- Currently enrolled in another investigational drug or device trial
- Previously enrolled in this trial
- Any condition making the patient unsuitable for enrollment, including end stage chronic illness with no reasonable expectation of survival to hospital discharge
- Known hypersensitivity to hemofilter
- Has received an organ transplant
- Expected to die within 24 hours
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
Research Team
J
Jiayun Ying
CONTACT
G
Guoping Lu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here